Fig. 8.

PKC inhibits SOCE. SOCE responses as determined by area under the curve (AUC) for PASMC pretreated with the PKC activator VII CGK062 (30 μM) or myristoylated-PKC inhibitor (myr-PKC, 10 μM; A). Responses in the presence of CGK062 were additionally assessed in the presence of FSC231 (B) and the percent PKC-induced inhibition of SOCE under vehicle and FSC231 treatments was determined (C). Values are means ± SE; n = 5–6/group; *P < 0.05 vs. vehicle; #P < 0.05 vs. non-CGK062, analyzed with t-test (C), one-way (A) or two-way (B) ANOVA, and individual groups compared with the Student-Newman-Keuls test.